Announcements
30 April 2025
Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award
We are pleased to announce that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.
 Richard DiMarchi Indiana University, USA |
Prof. Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, USA. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame. Dr. DiMarchi is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humulin®, Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon and incretin physiology and pioneered the discovery of single-molecule multi-mechanism agonists for the treatment of diabetes and obesity. The central element to success has been the chemical vision and technology to install within single molecules simultaneous agonism at related G-protein coupled receptors, coupled to the counter-intuitive discovery that glucagon and GIP agonism could synergize the therapeutic efficacy of GLP-1. These peptides and their conceptual approach have transformed the management of excessive body weight to a condition comparable to how hypertension, adult-onset diabetes, and excess cholesterol are medicinally managed. |
| “Professor DiMarchi was recognized by the 2024 Tu Youyou Award Committee members as being an exceptional leader in the medicinal chemistry of peptides and proteins of natural origin, and as a pioneer in the field of chemical biotechnology. His very important discoveries have led to breakthroughs in new drugs related to the therapy of diabetes and obesity. He has been named as an inventor on a very large number of patents, and he has had initially a highly successful scientific and administrative career in industry, which was followed by over two decades in academia as a distinguished professor.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee |
|
 Rolf Müller Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany; Helmholtz Centre for Infections Research (HZI), Germany; Saarland University, Germany |
Prof. Rolf Müller is the Founding and Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biotechnology at Saarland University, Germany. Having received his training from the University of Bonn, he held research positions at the University of Washington, USA, and Braunschweig University of Technology, Germany, prior to his appointment as professor to Saarland University. His laboratory has dedicated itself to the exploration of bacterial natural-product biosynthetic pathways for more than 20 years and has extensive experience in working with myxobacteria and other microbial producer strains. Starting from the isolation and characterization of new microorganisms, the scope of work includes microbiology-, biotechnology-, bioinformatics-, and chemistry-based approaches to exploit these isolates as sources of new drugs with a special focus on novel anti-infectives. Müller and his team apply a variety of state-of-the-art analytical methods and biological assays to perform biological and chemical characterizations of the identified compounds. Prof. Müller has received several awards, including the prestigious Gottfried Wilhelm Leibniz Prize, the PHOENIX Pharmacy Research Award, the DECHEMA Prize, and the Inhoffen Medal, as well as being an elected member of acatech, Leopoldina, and the German Academy of Sciences and Literature. |
| “The 2024 Tu Youyou Award Committee members were highly impressed by the truly outstanding past and ongoing contributions of Professor Müller in both microbial natural products isolation chemistry and in biosynthesis, as well as in the development of lead compounds for their potential in treating human diseases, through his global connections with various major funding agencies. He is also a dedicated teacher who has trained numerous graduate students and postdoctoral fellows, and he has lectured on his research in countries all over the world.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee |
|
The achievements of Richard DiMarchi and Rolf Müller highlight the transformative impact of natural products chemistry and medicinal chemistry. We congratulate them and invite the global academic community and public to join us in celebrating their significant contributions.
2024 Award Committee
Committee Chair:
- Prof. Dr. A. Douglas Kinghorn, Ohio State University, USA.
Committee Members (listed in alphabetical order):
- Prof. Angelo Fontana, University of Naples “Federico II”, Italy;
- Prof. Binghe Wang, Georgia State University, USA;
- Dr. Diana Pinto, University of Aveiro, Portugal;
- Prof. Hideaki Kakeya, Kyoto University, Japan;
- Dr. RuAngelie Edrada-Ebel, University of Strathclyde, UK;
- Prof. Thomas Prisinzano, University of Kentucky, USA
- Prof. Wei Li, University of Tennessee Health Science Center, USA.
About the Tu Youyou Award:
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honor the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award honoring exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.
For further information about the award and the winners, please visit the Tu Youyou Award website.
22 May 2025
Children | Highly Cited Papers Published in 2023–2024 in the “Pediatric Emergency Medicine and Intensive Care Medicine” Section
21 May 2025
Meet Us at the Annual Meeting of the American Psychological Association 2025 (APA 2025), 7–9 August 2025, Denver, USA
21 May 2025
Children | Highly Cited Papers Published in 2023–2024 in the “Pediatric Pulmonary and Sleep Medicine” Section
21 May 2025
Children | Highly Cited Papers Published in 2023–2024 in the “Pediatric Drugs” Section
19 May 2025
Meet Us at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases, 26–30 May 2025, Bucharest, Romania
13 May 2025
Empowering Academic Growth with MDPI: A Scientific Publishing Exchange at Toronto Metropolitan University, 15 May 2025
MDPI is excited to collaborate with Toronto Metropolitan University to host an engaging Scientific Publishing Workshop aimed at empowering scholars with the knowledge and tools needed to succeed in academic publishing. This workshop will delve into the key aspects of MDPI’s open access publishing framework, offering an in-depth exploration of journal selection, the editorial workflow, and the essentials of publication ethics. Participants will also gain practical advice on improving their scientific writing and effectively addressing reviewer comments, with guidance from an experienced professional. This session promises to equip attendees with valuable skills to elevate their publishing journey.
Workshop Highlights:
- Learn How to Better Write and Structure a Research Article;
- How to Choose Where to Publish Academic Work;
- How to Respond to Reviewer Comments;
- Reasons for Rejection During Pre-Check;
- How to Navigate Through Ethics and AI Use.
Date: 15 May 2025
Time: 12:00–1:30 p.m.
Venue: Toronto Metropolitan University
Program:
|
Speakers |
Program and Content |
Time |
|
Dr. Stephen Mora |
Introduction to MDPI |
12:00–12:05 p.m. |
|
|
How to Write and Structure a Research Article |
12:05–12:45 p.m. |
|
|
How to Respond to Reviewer Comments |
12:45–1:30 p.m. |
6 May 2025
World Asthma Day—“Make Inhaled Treatments Accessible for All”, 6 May 2025
World Asthma Day is held on the first Tuesday in May, aiming to improve asthma awareness and care around the world. World Asthma Day is organized by the Global Initiative for Asthma (GINA), a World Health Organization collaborative organization founded in 1993. In celebration of World Asthma Day 2025, GINA has chosen the theme “Make Inhaled Treatments Accessible for All”. GINA emphasizes the need to ensure that people with asthma can access inhaled medications that are essential both for controlling the underlying disease and treating attacks.
Asthma is one of the most common chronic non-communicable diseases that affects over 260 million people and is responsible for over 450,000 deaths each year worldwide. Most of these deaths are preventable. Inhaled corticosteroid-containing medications prevent asthma attacks by treating the underlying inflammation that causes asthma. Doctors and allied health care professionals are called upon to ensure that every person with asthma is prescribed evidence-based, essential, inhaled corticosteroid-containing medication in addition to (or in combination with) reliever medication, to prevent the continuing but avoidable morbidity and mortality from asthma.
In celebration of this day, we invite you to explore a curation of insightful articles, journals, and Special Issues across various fields, including human diseases and conditions, human nutrition, children’s health, and personalized medicine. By sharing these findings, we hope to call on everyone to increase our efforts in managing asthma to reduce and prevent attacks.
|
|
|
|
|
|
|
|
|
“Burden and Economic Impact of Respiratory Viral Infections in Adults Aged 60 and Older: A Focus on RSV”
by Adrián Peláez, Sara Jimeno Ruiz, Mercedes Villarreal, Manuel Gil, Inés Gutiérrez, Marta Sanz and Silvina Natalini Martínez
Diseases 2025, 13(2), 35; https://doi.org/10.3390/diseases13020035
“Long-Term Greenness Effects of Urban Forests to Reduce PM10 Concentration: Does the Impact Benefit the Population Vulnerable to Asthma?”
by Jinsuk Jeong, Chaewan Kim, Sumin Choi, Hong-Duck Sou and Chan-Ryul Park
Int. J. Environ. Res. Public Health 2025, 22(2), 167; https://doi.org/10.3390/ijerph22020167
“Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A “Real-Life” Observational Study”
by Eugenio De Corso, Dario Antonio Mele, Angela Rizzi, Camilla Spanu, Marco Corbò, Serena Pisciottano, Rodolfo Francesco Mastrapasqua, Silvia Baroni, Davide Paolo Porru, Gabriele De Maio et al.
J. Pers. Med. 2024, 14(9), 1014; https://doi.org/10.3390/jpm14091014
“Current Challenges in Pediatric Asthma”
by Andrija Miculinić, Iva Mrkić Kobal, Tin Kušan, Mirjana Turkalj and Davor Plavec
Children 2024, 11(6), 632; https://doi.org/10.3390/children11060632
“Prediction of Asthma Exacerbations in Children”
by Evangelia Sarikloglou, Sotirios Fouzas and Emmanouil Paraskakis
J. Pers. Med. 2024, 14(1), 20; https://doi.org/10.3390/jpm14010020
“Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma”
by Clara Padró-Casas, María Basagaña, María Luisa Rivera-Ortún, Ignasi García-Olivé, Carlos Pollan-Guisasola, Aina Teniente-Serra, Eva Martínez-Cáceres, José-Tomás Navarro, Jorge Abad-Capa, Antoni Rosell et al.
J. Pers. Med. 2023, 13(7), 1173; https://doi.org/10.3390/jpm13071173
“Association between Single Nucleotide Polymorphisms Related to Vitamin D Metabolism and the Risk of Developing Asthma”
by Susana Rojo-Tolosa, Laura Elena Pineda-Lancheros, José María Gálvez-Navas, José Antonio Sánchez-Martínez, María Victoria González-Gutiérrez, Andrea Fernández-Alonso, Concepción Morales-García, Alberto Jiménez-Morales and Cristina Pérez-Ramírez
Nutrients 2023, 15(4), 823; https://doi.org/10.3390/nu15040823
“Racial Disparities and Common Respiratory Infectious Diseases in Children of the United States: A Systematic Review and Meta-Analysis”
by Elizabeth A. K. Jones, Amal K. Mitra and Shelia Malone
Diseases 2023, 11(1), 23; https://doi.org/10.3390/diseases11010023
“Microbiome and Asthma: Microbial Dysbiosis and the Origins, Phenotypes, Persistence, and Severity of Asthma”
by José Valverde-Molina and Luis García-Marcos
Nutrients 2023, 15(3), 486; https://doi.org/10.3390/nu15030486
“Effect of Disease Severity, Age of Child, and Clinic No-Shows on Unscheduled Healthcare Use for Childhood Asthma at an Academic Medical Center”
by Pavani Rangachari, Imran Parvez, Audrey-Ann LaFontaine, Christopher Mejias, Fahim Thawer, Jie Chen, Niharika Pathak and Renuka Mehta
Int. J. Environ. Res. Public Health 2023, 20(2), 1508; https://doi.org/10.3390/ijerph20021508
|
“Pulmonary Function in Children with Respiratory Symptoms” |
“Mechanisms of Airway Inflammation in Asthma” |
 |
 |
30 April 2025
MDPI INSIGHTS: The CEO's Letter #22 - 300 Journals in WoS, Norway & Sweden Consortiums, Self-citations
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
Over 300 MDPI Journals are Indexed in Web of Science
Indexing is essential to scholarly publishing as it promotes visibility and the impact of research. I’m excited to share that MDPI now has over 300 journals indexed in the Web of Science (WoS). This milestone reflects the work of our authors, editors, reviewers, and the entire MDPI staff, contributing to greater visibility and impact for open access research.
Publish with MDPI, publish with impact.
Having over 300 MDPI journals indexed in the Web of Science is more than a numbers game. It represents a recognition of the quality, consistency, and relevance of the research published in our journals. For the academic community, it reflects the growing trust in MDPI as a reputable publisher, leading the way in open access publishing.
A closer look at the achievement
Being indexed in the WoS nvolves meeting a list of quality criteria, including 24 quality benchmarks for ESCI journals.
For MDPI, rigorous editorial standards and scientific integrity are key. These enabled over 300 journals to pass the Web of Science quality criteria for indexing.
Here we share a blog post discussing the importance of this milestone for MDPI and open scholarly research. In this post, Constanze Schelhorn, Head of Indexing, at MDPI, and Giulia Stefenelli, Scientific Communications Lead, share their thoughts and insights on what this achievement means for our commitment to high-quality research.
“MDPI has a well-structured quality assurance framework that applies to all our journals. We also apply clear, standardized peer-review policies across our portfolio, ensuring transparency and consistency.” – Constanze Schelhorn, Head of Indexing
“This achievement is a step forward for Open Access research, reinforcing the mission to share scientific knowledge globally and facilitate research progress.” – Giulia Stefenelli, Scientific Communications Lead
Read the blog here: https://blog.mdpi.com/2025/04/03/300-mdpi-journals/
Looking to the future
This milestone is a testament to MDPI’s dedication to peer review, editorial excellence, and innovation in academic publishing. It highlights our role as leaders in open access publishing.
Personally, I see this as just the beginning. We will continue to support researchers, expand our contributions to scholarly communication, and push the boundaries of academic publishing.
Impactful Research
Nearly 920 partner institutions in MDPI’s Institutional Open Access Program
I’m pleased to share some exciting progress from MDPI's Institutional Open Access Program (IOAP), which now includes nearly 920 partner institutions worldwide. This is more than just a number. It reflects the growing trust and collaboration we’ve built with universities, libraries, and research organizations across the globe.
The IOAP offers institutions discounted Article Processing Charges (APCs), access to a dedicated institutional dashboard, and transparency throughout the publishing process.
Norway’s Sikt Consortium Renews national agreement with MDPI
MDPI has renewed its national agreement with the Sikt Consortium, which now supports 36 institutions across Norway. New partners, such as Kristiania University of Applied Sciences, join long-standing collaborators such as NTNU, the University of Bergen, and UiT, The Arctic University of Norway. The agreement promotes affordable, high-quality open access publishing through centralized APC funding, and reinforces Norway’s leadership in open science.
These agreements reflect MDPI’s mission to remove barriers to scientific publishing and make research freely available to all. By collaborating with national consortia and institutions, we advance the open access and strengthen our global network and collaborations.
Our IOAP Team
A big thank-you to our IOAP team for driving these important collaborations. Their work includes increasing MDPI’s visibility in scholarly communications, strengthening relationships with IOAP partners, and building trust with key stakeholders.
These efforts not only help researchers to publish their work openly and affordably but also reinforce MDPI’s position as a trusted leader in open access.
What are the benefits of MDPI’s IOAP?
For Authors: Researchers affiliated with IOAP partner institutions benefit from automatic discounts on APCs, Book Processing Charges (BPCs), JAMS, and Author Services across MDPI’s journals. The process is seamless as there is no need for codes or special applications. The publishing experience is smoother and more affordable, and centralized invoicing helps simplify the process, allowing authors to focus on their research rather than administration.
For Libraries: Participating libraries receive access to a dedicated institutional dashboard with live metadata on submissions from affiliated authors, past and present. They also benefit from flexible invoicing options (direct, collective, or prepayment) to help streamline administration, while clear, transparent agreements ensure that there are no hidden clauses or small print. Automated deposits into Institutional Repositories further reduce manual work, supporting libraries in their mission to advance open access and serve their research communities.
Inside MDPI
MDPI Self-citation study shows industry alignment
Earlier this month, Dr. Giulia Stefenelli and Dr. Enric Sayas published a thoughtful and transparent article on the ALPSP blog, presenting a self-citation analysis across MDPI’s 237 journals indexed in the Journal Citation Reports (JCR).
They found that MDPI's average self-citation rate in 2024 was 14.85%, well within industry norms and ranking 6th among the top ten publishers. Only 2.3% of MDPI journals were identified as outliers with high self-citation rates, compared to 4.7% among other leading publishers. An alternative approach, using weighted average by publication volume, shows MDPI’s self-citation rate rises from 14% to 19.7%, shifting our rank from 6th to 3rd. The study also shows that the impact of self-citation on journal quartile placement is minimal.
Read the full article on the ALPSP blog: https://blog.alpsp.org/2025/03/mdpi-self-citations-study-highlights.html
Why is this important?
As explained in the full article, the results “reinforce the fact that self-citations have minimal influence on MDPI journal rankings, emphasizing the integrity of editorial practices and the absence of any deliberate efforts to manipulate impact.”
Self-citation is a hot topic, and MDPI is sometimes unfairly singled out in this area. This analysis helps put some perspective to that narrative.
At MDPI, we are committed to transparency and to using data-driven insights to address common misconceptions about open access publishing. Our focus on self-citation reflects this commitment, and we plan to extend our efforts to other areas where the Gold OA model is often misunderstood.
About the authors
Dr. Giulia Stefenelli, Scientific Communications Lead, leverages her expertise in science communication, editorial processes, and Open Access (OA) promotion to address both institutional and country-specific challenges. She collaborates with teams across PR, Editorial Procedures, Institutional Partnerships, Research Integrity, AI and more, developing strategies to engage stakeholders, including policymakers, academics, and industry leaders. Her responsibilities include enhancing MDPI’s scientific network and promoting OA initiatives at events worldwide, supporting the efforts of various departments, and ensuring effective communication to both specialist and broader audiences.
Dr. Enric Sayas is a Business Analyst specializing in the integration of AI and Machine Learning in scientific publishing.
Within MDPI’s AI team, Enric combines his editorial expertise with his passion for AI to support the development of AI-driven solutions tailored to editorial needs, enhancing efficiency and improving decision-making.
Enric’s interests extend to data science methodologies applied to scientific publishing, as well as the broader impact of AI on open science, peer review, and the future of scientific publishing.
Coming Together for Science
Plants 2025: From Seeds to Food Security
Prof. Dr. Dilantha Fernando presenting at Plants 2025 in Barcelona, Spain.
The MDPI Conference Plants 2025: From Seeds to Food Security took place in Barcelona, Spain, from 31 March to 2 April 2025.
It was chaired by Editor-in-Chief of MDPI journal Plants (Q1 journal); Prof. Dr. Dilantha Fernando from the University of Manitoba, in Canada, and Section Editor-in-Chief of Plants; Dr. Fermín Morales from Instituto de Agrobiotecnología (IdAB) – CSIC, in Spain; and Prof. Dr. Oscar Vicente from Universitat Politècnica de València (UPV) in Spain.
The conference brought plant scientists together to discuss innovations in sustainable agriculture, crop improvement, and environmental conservation.
With the global population projected to reach 9.7 billion by 2050, the conference addressed key challenges such as food security, climate change, and sustainable agroecosystems through keynote talks and seven specialized sessions.
The conference gathered 111 attendees from 36 different countries, featuring 1 keynote speaker, 9 invited speakers, and 41 selected talks, along with 56 posters. The event received just over 200 submissions and 102 accepted abstracts.
From insightful talks, engaging poster sessions and engaging networking moments, Plants 2025 was a special experience. You can relive the highlights from the Plants 2025 conference here with our after movie!
Awards
Four awards were presented at the conclusion of the conference, sponsored by the journal Plants: two Best Poster Awards (€250 each) and two Best Oral Presentation Awards (€300 each).
Plants 2025 Conference Team
The Plants 2025 Conference was organized by colleagues from MDPI’s Conference Team: Ana Sanchis (Conference Manager), Cédric Spinnler (Senior Conference Organizer), Raquel Sellès (Conference Organizer) and Laura Perez (Conference Assistant).
Upcoming event
5–7 May 2025
The 2nd International Electronic Conference on Metals
Location: Online event (Central European Summer Time)
As one of the pillar technologies that support the development of modern society and metallurgy, IECME 2025 will present the state-of-the-art of Metallurgy and Metals.
Find more upcoming MDPI events here.
Closing Thoughts
Swedish consortium renews partnership with MDPI
I’m pleased to share that MDPI has renewed its national partnership with Sweden’s Bibsam Consortium. This is a continued commitment to advancing open access publishing and supporting Sweden’s vision for fully open research.
Under this renewed agreement, 22 leading institutions including KTH Royal Institute of Technology, Stockholm University, Linnaeus University, and Linköping University, will continue to benefit from MDPI’s IOAP. This provides discounts on APCs and a more streamlined, researcher-friendly publishing experience.
MDPI and Bibsam renew national agreement for Sweden
“With robust backing from national open science guidelines, Sweden’s open-access landscape is rapidly advancing,” says Becky Castellon, institutional partnerships manager at MDPI.
“In fact, fewer than 15% of all Swedish research outputs were locked behind paywalls in 2023. We are passionate about the positive impact our ongoing partnership with the Bibsam Consortium will have on Swedish research, paving the way for ground-breaking developments and a more inclusive, open scientific community. Through flexible solutions and tailored policies, we enable institutions to prioritize research, foster innovation, and enhance accessibility, driving the shift to full open access.”
Recent MDPI IOAP Consortium signings from 2025:
- The UK’s Jisc Consortium extended its national agreement, continuing support for more than 60 institutions across the UK.
- Switzerland’s CSAL (Consortium of Swiss Academic Libraries) renewed its agreement, continuing our collaboration with top institutions such as ETH Zurich and EPFL Lausanne.
- In Germany, we signed a new national agreement with ZB MED that includes over 100 universities and research institutions, with 78 institutions joining under a central or flat-fee model to simplify APC coverage.
Chief Executive Officer
MDPI AG
30 April 2025
Announcing the Award Committee for the 2024 Tu Youyou Award
We are honored to introduce the award committee for the 2024 Tu Youyou Award, composed of distinguished scientists from around the world whose research covers diverse areas of natural product chemistry, pharmacognosy, and drug discovery. Their broad expertise and pioneering contributions have significantly advanced medicinal and natural products research.
Through their collective insights, rigorous evaluation, the committee has carefully selected this year’s award recipients, recognizing exceptional achievements in the field.
We sincerely thank these distinguished scholars for their efforts and dedication to upholding the standards of the Tu Youyou Award. Below is the list of committee members. For more information about the Tu Youyou Award, please visit https://tuyouyouprize.org/.
Chair:
 Prof. Dr. A. Douglas Kinghorn Ohio State University, USA |
Prof. Dr. A. Douglas Kinghorn is a leading expert in pharmacognosy and natural products research. He is recognized for his key contributions to discovering bioactive compounds from plants, especially in anticancer, cancer chemopreventive, and substances with a sweet taste and taste-modifying agents. His prolific contributions include over 590 peer-reviewed works and book chapters and edited or co-edited 40 scientific volumes. |
 Prof. Angelo Fontana University of Naples “Federico II”, Italy |
Angelo Fontana is a Professor of Organic Chemistry at the University of Naples “Federico II” in Italy and serves as Director of the Institute of Biomolecular Chemistry at the National Research Council (CNR). His research focuses on bioactive small molecules derived from marine eukaryotes, with a particular interest on their pharmaceutical applications in immunology and oncology. He also explores their potential as molecular tools for probing and modulating complex biological systems. Prof. Fontana is a co-founder of BioSEArch SRL and has been recognized with numerous grants and honors, including the Apivita Award from the Phytochemical Society of Europe. |
 Prof. Binghe Wang Georgia State University, USA |
Prof. Binghe Wang’s lab works on drug design, drug delivery, click chemistry, chemical biology, new diagnostics, and gaseous signaling molecules such as carbon monoxide and hydrogen sulfide. His interdisciplinary research supports advances in cancer, infectious diseases, organ protection, inflammation, and other areas. |
 Dr. Diana Pinto University of Aveiro, Portugal |
Dr. Diana Pinto, an Associate Professor at the University of Aveiro, specializes in organic synthesis of bioactive heterocyclic compounds, sustainable catalysis (organo-, heterogeneous, and biocatalysis), and natural product research, including isolation, characterization, and total synthesis. |
 Prof. Hideaki Kakeya Kyoto University, Japan |
Prof. Hideaki Kakeya conducts cutting-edge research in chemical biology, high-throughput screening, and biosynthesis of bioactive natural products for system chemotherapy and other therapeutic applications. |
 Dr. RuAngelie Edrada-Ebel University of Strathclyde, UK |
Prof. RuAngelie Edrada-Ebel heads the Natural Products Metabolomics Group (NPMG), specializing in marine natural products discovery and metabolomics-driven drug development. A recognized expert in bioactive metabolites, she collaborates with industry and academia to address antimicrobial resistance and sustainable bioprospecting. She serves on the Editorial Board of Marine Drugs and holds two patents in the field. |
 Prof. Thomas Prisinzano University of Kentucky, USA |
Prof. Thomas Prisinzano combines medicinal and natural product chemistry to explore neurotransmitter systems and develop treatments for drug abuse and pain. He has received several prestigious awards, including the Innovator Award from the College on Problems of Drug Dependence. |
 Prof. Wei Li University of Tennessee Health Science Center, USA |
A distinguished professor and Director of the Drug Discovery Center, Prof. Wei Li is also the founder of SEAK Therapeutics, and the 2025 Chair-Elect of the Drug Discovery and Development Division of the American Society of Pharmacology and Experimental Therapeutics (ASPET). His work focuses on medicinal chemistry and small molecule drug discovery, with over 200 publications and 15 issued US patents. |
